Egypt
Key Insights
- 1
No psychedelic therapy is approved in Egypt; ketamine is the only documented legal compound, used under controlled medical supervision rather than patient access to psychedelics.
- 2
The database shows 2 trials, 0 active, and 2 research organisations, with ketamine and placebo the only studied compounds.
- 3
Egypt’s clinical footprint is anaesthesia-led, not psychiatric: published trials from Cairo, Assiut and Tanta universities centre on ketamine, not psilocybin or MDMA.
- 4
Momentum is regulatory, not commercial: the Egyptian Drug Authority issued ketamine guidance in 2025, tightening supervised use and curbing misuse.
Reimbursed Care Access
Egypt maintains a highly restrictive national drug control regime with criminal penalties for unauthorized possession or use of narcotics and psychotropic substances; however, ketamine is an established, controlled medicinal anesthetic and is used in Egyptian hospitals and research settings. Other classic psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, ayahuasca, mescaline, 2C‑X) have no authorized medical market access outside approved clinical research and remain controlled under Egypt's narcotics/psychotropic laws.
Quick Indicators
Organizations
2Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in Egypt.